Update shared on 19 Nov 2025
Fair value Increased 6.25%Analysts have raised their price target for Supriya Lifescience from ₹800 to ₹850, citing stronger revenue growth projections and improved profit margins.
What's in the News
- The board meeting is scheduled for November 12, 2025 to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025. The meeting will also review the statutory auditors' limited review report (Company filing).
- The Ambernath facility received WHO-GMP certification following a successful audit. This enables production, sale, and export of inhalation dosages to eligible global markets (WHO/Company filing).
- A final dividend of INR 1.00 per equity share for the year ended March 31, 2025 was approved at the 17th Annual General Meeting held on September 24, 2025 (AGM resolution).
Valuation Changes
- Consensus Analyst Price Target has increased from ₹800 to ₹850. This reflects higher confidence in future performance.
- Discount Rate has risen slightly, moving from 12.73% to 12.76%.
- Revenue Growth projection has edged up to 26.37%, compared to the prior 23.11%.
- Net Profit Margin forecast has improved modestly to 24.97%, up from 24.54%.
- Future P/E ratio expectation has declined to 27.07x from 29.03x. This indicates stronger earnings anticipation relative to price.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.